NeuroSense Therapeutics Ltd. Reports Q3 2024 Results
Ticker: NRSNW · Form: 6-K · Filed: Dec 18, 2024 · CIK: 1875091
Sentiment: neutral
Topics: financial-results, business-update, foreign-private-issuer
TL;DR
NeuroSense dropped its Q3 2024 update and financials on 12/18.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on December 18, 2024, to report its business update and third quarter 2024 financial results. The company, headquartered in Herzliya, Israel, is a pharmaceutical preparations company.
Why It Matters
This filing provides investors with an update on the company's progress and financial performance, crucial for evaluating its current standing and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, NeuroSense faces inherent risks related to drug development and regulatory approvals.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- December 18, 2024 (date) — Date of the press release and filing
- Third Quarter 2024 (period) — Financial results reported
- Herzliya, Israel (location) — Company headquarters
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is filed to report a business update and the third quarter 2024 financial results of NeuroSense Therapeutics Ltd., as detailed in a press release issued on December 18, 2024.
When did NeuroSense Therapeutics Ltd. issue the press release mentioned in the filing?
The press release, titled 'NeuroSense Management Provides Business Update and Third Quarter 2024 Financial Results,' was issued on December 18, 2024.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
What type of company is NeuroSense Therapeutics Ltd. classified as by the SEC?
The company is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Does NeuroSense Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
NeuroSense Therapeutics Ltd. indicates that it files annual reports under Form 20-F.
Filing Stats: 287 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-12-18 11:06:44
Filing Documents
- ea0225194-6k_neuro.htm (6-K) — 11KB
- ea022519401ex99-1_neuro.htm (EX-99.1) — 85KB
- ex99-1_001.jpg (GRAPHIC) — 25KB
- 0001213900-24-110006.txt ( ) — 131KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: December 18, 2024 By: /s/ Alon Ben-Noon 3